



28th February 2011

Company Announcements Office
Australian Securities Exchange

Trophon EPR receives FDA clearance for the US market

Nanosonics is pleased to announce that it has today received FDA 510k clearance to market the Trophon EPR and our newly developed Chemical Indicator accessory into the US market.

This significant achievement will allow Nanosonics to commence a staged release of product into the world's largest ultrasound market, where there are in excess of 200 million ultrasound examinations performed annually.

As has been previously advised, Nanosonics is on track with the finalisation of the GE distribution contract for the USA and Canada. This FDA clearance will allow the Company to commence working with Key Opinion Leaders throughout the USA.

The Company acknowledges the outstanding efforts of the entire team in the achievement of this significant milestone in the commercialisation of the Trophon EPR.

David Radford
CEO

For more information please contact:
David Radford, CEO, on 02 8063 1600

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com.au